(Q38071383)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23286841%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

review article

1 reference

title

Optimal treatment with boceprevir for chronic HCV infection (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23286841%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23286841%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

2

Michael P Manns

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23286841%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

publication date

1 February 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23286841%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23286841%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

volume

33 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23286841%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

page(s)

14-22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23286841%20AND%20SRC:MED&resulttype=core&format=json

Evolving epidemiology of hepatitis C virus

21 February 2020

cites work

1 reference

Natural history of acute and chronic hepatitis C.

21 January 2018

1 reference

A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C.

21 January 2018

1 reference

Outcome of sustained virological responders with histologically advanced chronic hepatitis C.

21 January 2018

1 reference

Treating viral hepatitis C: efficacy, side effects, and complications

21 January 2018

1 reference

EASL Clinical Practice Guidelines: management of hepatitis C virus infection

21 January 2018

1 reference

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

21 January 2018

1 reference

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

Boceprevir for previously treated chronic HCV genotype 1 infection

21 January 2018

1 reference

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

Telaprevir for retreatment of HCV infection

21 January 2018

1 reference

Factors that predict response of patients with hepatitis C virus infection to boceprevir

21 January 2018

1 reference

Genomics and HCV infection: progression of fibrosis and treatment response

21 January 2018

1 reference

Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow

21 January 2018

1 reference

Preliminary study of two antiviral agents for hepatitis C genotype 1.

21 January 2018

1 reference

New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbye.

21 January 2018

1 reference

Predicted effects of treatment for HCV infection vary among European countries

21 January 2018

1 reference

Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity

21 January 2018

1 reference

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

21 January 2018

1 reference

Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis

21 January 2018

1 reference

Invasive and non-invasive methods for the assessment of fibrosis and disease progression in chronic liver disease.

21 January 2018

1 reference

Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C.

21 January 2018

1 reference

Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections

21 January 2018

1 reference

Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses.

21 January 2018

1 reference

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

21 January 2018

1 reference

Boceprevir dosing for late responders and null responders: the role of bridging data between treatment-naïve and -experienced subjects

21 January 2018

1 reference

Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin

21 January 2018

1 reference

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

21 January 2018

1 reference

Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues

21 January 2018

1 reference

Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers

21 January 2018

1 reference

Review and management of drug interactions with boceprevir and telaprevir

21 January 2018

1 reference